SEC Tracker
Get the app
TGTX · XBRL financial data

TG Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (TGTX's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers16644*637384108*121141162193*205240
Cost of goods and services sold4year only58915*16192838*3441
Research and development1517*33182024*46324141*4895
Selling, general and administrative3331*35394239*50566363*8882
Operating income (loss)115(12)*(9)91230*9352950*3522
Interest expense42*24117*7777*817
Other income (expense)31*1233*4331*25
Income tax expense (benefit)00*0(0)02*03(365)22*12
Net income (loss)114(14)*(11)7423*52839123*208
Earnings per share, basic USD per share0.80(0.10)*(0.07)0.050.030.16*0.030.192.690.17*0.140.05
Earnings per share, diluted USD per share0.73—(0.07)0.040.020.13*0.030.172.430.14*0.120.05
Weighted average shares, basic millions of shares143143*146145145145*147147145139*144142
Weighted average shares, diluted millions of shares156156*146159161175*163163161159*160157

Balance sheet

CSV

Fiscal quarters (TGTX's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents1519375831961801321297479442483
Short-term investments7812513413414513114412358637270
Accounts receivable—516584116129190232265306392402
Inventory3440788185110158155147126129148
Total current assets3193183613895745666456646006311,0871,146
Property and equipment, net000—————————
Right-of-use asset888877777667
Goodwill111—————————
Total assets3313303734015865786577031,0251,0631,5291,640
Current portion of long-term debt0———————————
Total current liabilities585410010912591160172157154187268
Long-term debt99100101103244244245245245246745745
Lease liability, non-current1099988887777
Total liabilities1661692132243943554194264184159461,036
Accumulated deficit(1,500)(1,514)(1,525)(1,556)(1,553)(1,529)(1,524)(1,496)(1,105)(1,082)(1,062)(1,054)
Total stockholders' equity165161160178192222237276607648583604
Total liabilities and equity3313303734015865786577031,0251,0631,5291,640
Common shares outstanding (cover page) millions of shares151154155155156157159159159160153153

Cash flows

CSV

Fiscal quarters (TGTX's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)114(14)*(11)7423*52839123*208
Stock-based compensation9*9*99*12*12*1516*18*16*2028*
Depreciation and amortization0*0*00*0*0*00*0*0*00*
Net cash from operating activities84*(13)*(8)6*(12)*(26)*(29)7*(23)*20*(18)39*
Purchases of property and equipment—0*00*0*0*00*0*0*00*
Net cash from investing activities(30)*(45)*(9)2*(9)*16*(13)(4)*46*(16)*(10)1*
Proceeds from issuing common stock0*(0)*——0*0*———year only——
Net cash from financing activities0*(0)*00*134*(6)*(6)(6)*(78)*1*3910*
Net change in cash54*(58)*(17)7*113*(16)*(48)(3)*(55)*5*36340*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
TG Therapeutics48324039*153.1M— 10-QJun 30, 2026
Cytokinetics25529(160)*139.0M7.3 quarters 10-QJun 30, 2026
Catalyst Pharmaceuticals75614960122.4M— 10-QMar 31, 2026
Summit Therapeutics419not reported(141)*797.7M4.9 quarters 10-QJun 30, 2026
Xenon Pharmaceuticals120not reported(95)*96.8M9.8 quarters 10-QJun 30, 2026
Twist Bioscience117not reported1.1*62.7M— 10-QJun 30, 2026
Acadia Pharmaceuticals385308101*172.3M— 10-QJun 30, 2026
Protagonist Therapeutics420213219*64.7M— 10-QJun 30, 2026
Prestige Consumer Healthcare892667147.4M— 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.